Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 19, 2022
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
Tue, January 18, 2022
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
Matthew Harrison Maintained (BGNE) at Buy with Decreased Target to $360 on, Jan 18th, 2022
Matthew Harrison of Morgan Stanley, Maintained "BeiGene, Ltd." (BGNE) at Buy with Decreased Target from $407 to $360 on, Jan 18th, 2022.
Matthew has made no other calls on BGNE in the last 4 months.
There are 2 other peers that have a rating on BGNE. Out of the 2 peers that are also analyzing BGNE, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matthew
- Andrew Berens of "SVB Leerink" Maintained at Buy with Decreased Target to $414 on, Thursday, October 14th, 2021
- Rebecca Liang of "Bernstein" Initiated at Buy and Held Target at $431 on, Tuesday, October 12th, 2021
